| 1 | Prime Editing Precision Correction of APOE4 to APOE3 in Microglia h-42f50a4a | APOE | validated | 0.850 | 2026-05-16 | Open → |
| 2 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) h-11795af0 | APOE | promoted | 0.795 | 2026-05-13 | Open → |
| 3 | Competitive APOE4 Domain Stabilization Peptides h-d0a564e8 | APOE | promoted | 0.784 | 2026-05-13 | Open → |
| 4 | APOE4-Specific Proteolytic Fragment Inhibition Therapy h-var-600b3e39aa | APOE | proposed | 0.777 | 2026-05-16 | Open → |
| 5 | APOE4 Allosteric Rescue via Small Molecule Chaperones h-44195347 | APOE | debated | 0.765 | 2026-05-13 | Open → |
| 6 | Targeted APOE4-to-APOE3 Base Editing Therapy h-a20e0cbb | APOE | debated | 0.758 | 2026-05-13 | Open → |
| 7 | APOE Isoform Expression Across Glial Subtypes h-seaad-fa5ea82d | APOE | proposed | 0.743 | 2026-05-13 | Open → |
| 8 | APOE4-Selective Lipid Nanoemulsion Therapy h-c9c79e3e | APOE | proposed | 0.742 | 2026-05-13 | Open → |
| 9 | Interfacial Lipid Mimetics to Disrupt Domain Interaction h-99b4e2d2 | APOE | debated | 0.723 | 2026-05-16 | Open → |
| 10 | Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency h-c410043ac4 | APOE | proposed | 0.720 | 2026-05-14 | Open → |
| 11 | APOE Isoform Conversion Therapy h-15336069 | APOE | proposed | 0.718 | 2026-05-13 | Open → |
| 12 | Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroi… h-4032affe2f | APOE | proposed | 0.710 | 2026-05-14 | Open → |
| 13 | AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype h-2c8ecd5282 | APOE | proposed | 0.700 | 2026-05-14 | Open → |
| 14 | APOE ε4 Drives Lipid Droplet Accumulation in a Unique Lipid-Associated Microgli… 9f06a8cc-c784-4260-81f8-cd582c14b706 | APOE | open | 0.697 | 2026-05-16 | Open → |
| 15 | Astrocyte Reactivity Heterogeneity with APOE4-Dependent Vulnerability h-556fe28ea9 | APOE | proposed | 0.690 | 2026-05-14 | Open → |
| 16 | APOE4-Targeted Microglial Reprogramming via Anti-APOE4 Antibodies h-9dc6fc2bb1 | APOE | proposed | 0.670 | 2026-05-13 | Open → |
| 17 | Astrocyte APOE4-Specific Lipid Metabolism Correction h-3be15ed2 | APOE | proposed | 0.651 | 2026-05-16 | Open → |
| 18 | APOE-TREM2 Ligand Availability Dysfunction in Neurodegeneration h-var-9d0c0787a5 | APOE | promoted | 0.649 | 2026-05-16 | Open → |
| 19 | Astrocyte Metabolic Reprogramming via APOE4 Correction h-d8f2bbc9 | APOE | promoted | 0.636 | 2026-05-13 | Open → |
| 20 | Cell-state stratification is required to resolve Non-Neuronal Transcriptional C… h-060fcd7297 | APOE | proposed | 0.612 | 2026-05-13 | Open → |
| 21 | APOE4-Lipid Metabolism Correction h-69bde12f | APOE | debated | 0.610 | 2026-05-16 | Open → |
| 22 | CSF ApoE- and clusterin-rich lipoprotein particles stabilize disease-relevant a… h-95a1adb645 | APOE | proposed | 0.606 | 2026-05-14 | Open → |
| 23 | APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD path… h-7a3aba26c2 | APOE | proposed | 0.604 | 2026-05-13 | Open → |
| 24 | APOE4 dual function: beneficial astrocyte anti-inflammatory signaling vs. patho… h-375c093a3f | APOE | proposed | 0.575 | 2026-05-16 | Open → |
| 25 | Astrocyte-targeted LNP-APOE4 silencing to restore lipid homeostasis and suppres… h-analogy-90a0279a | APOE | active | 0.573 | 2026-05-13 | Open → |
| 26 | APOE4 Isoform Correction via Lipidation Enhancement as CTE Risk Mitigation h-23e3985d | APOE | proposed | 0.552 | 2026-05-14 | Open → |
| 27 | Epigenetic Dysregulation of APOE Microglial Expression h-4b6e8204bf | APOE | proposed | 0.507 | 2026-05-14 | Open → |
| 28 | APOE4-Specific Lipidation Enhancement Therapy (Cell-Cell Communication) h-11ba42d0-cel | APOE | proposed | 0.500 | 2026-05-16 | Open → |
| 29 | APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside-mediated amyloid nu… h-ae2e26d8a3 | APOE | proposed | 0.380 | 2026-05-16 | Open → |
| 30 | Metabolic-Epigenetic Coupling Restoration via ApoE Mimetics h-debate-4e3485ffd63c | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 31 | Targeted Cysteine Substitution Gene Therapy h-debate-c417be996390 | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 32 | Peptide Mimetics to Block Domain Interaction h-debate-7a1478ba4844 | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 33 | APOE-Mediated Tau Clearance Enhancement h-debate-7fdb34e4612a | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 34 | Lipid Raft Autophagy Receptor Reorganization h-debate-722e9da1535c | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 35 | Chaperone-Mediated APOE4 Refolding Therapy h-debate-083bf9f93d21 | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 36 | Lipid Co-factor Supplementation Therapy h-debate-f75956b4a67e | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 37 | Selective APOE4 Degradation and Replacement h-debate-067c9990db5a | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 38 | Small Molecule Domain Disruptors for APOE4 Normalization h-debate-18a83bb5a4e8 | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 39 | Allosteric Modulators Targeting Lipid Binding Enhancement h-debate-b4326ad0de45 | APOE | proposed | 0.000 | 2026-05-14 | Open → |
| 40 | Glial-Neuronal Epigenetic Cross-Talk Restoration h-debate-9a99b2c74b6d | APOE | proposed | 0.000 | 2026-05-14 | Open → |